XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
CURRENT ASSETS:    
Cash and cash equivalents $ 13,206 $ 13,116
Accounts receivable, net of allowance for doubtful accounts of $2,789 and $2,650 at 2019 and 2018, respectively 132,859 129,157
Inventories 50,147 45,664
Prepaid expenses 14,433 15,351
Income taxes receivable 12,517 13,993
Other current assets 13,261 13,696
TOTAL CURRENT ASSETS 236,423 230,977
PROPERTY, PLANT AND EQUIPMENT, net 124,758 122,917
RIGHT OF USE ASSETS 77,537  
INTANGIBLES, net 12,887 13,054
GOODWILL 219,139 219,412
DEFERRED TAX ASSETS 64,657 11,252
OTHER ASSETS 56,359 51,215
TOTAL ASSETS 791,760 648,827
CURRENT LIABILITIES:    
Accounts payable 44,467 41,155
Accrued payroll and related costs 32,768 22,549
Taxes other than payroll and income 7,071 7,488
Unearned revenue 18,430 17,325
Operating lease liabilities 13,003  
Income taxes payable 2,326 2,917
Other current liabilities 10,550 11,113
TOTAL CURRENT LIABILITIES 128,615 102,547
LONG-TERM DEBT, net 294,896 289,770
LONG-TERM OPERATING LEASE LIABILITIES 64,090  
DEFERRED COMPENSATION 48,087 49,359
DEFERRED TAX LIABILITIES 29,281 7,634
OTHER LONG-TERM LIABILITIES 39,438 38,617
COMMITMENTS AND CONTINGENCIES
EQUITY:    
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding 0 0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,333,774 outstanding at 2019 and 44,796,252 issued and 44,316,845 outstanding at 2018 1,148 1,148
Additional paid-in capital 65,084 57,438
Retained earnings 172,266 156,130
Accumulated other comprehensive income (loss) (5,795) (5,456)
Treasury shares (at cost), 462,478 at 2019 and 479,407 at 2018 (49,538) (52,501)
Total Core Laboratories N.V. shareholders' equity 183,165 156,759
Non-controlling interest 4,188 4,141
TOTAL EQUITY 187,353 160,900
TOTAL LIABILITIES AND EQUITY $ 791,760 $ 648,827